- Home
- ILAG vs VIVS Comparison
ILAG vs VIVS Comparison
Compare ILAG & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ILAG | VIVS |
|---|---|---|
| Founded | 1981 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | 9 |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 4.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ILAG | VIVS |
|---|---|---|
| Price | $2.27 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.3K | ★ 57.8K |
| Earning Date | 04-27-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $1.38 |
| 52 Week High | $7.19 | $5.30 |
Technical Indicators
Market Signals| Indicator | ILAG | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 42.94 |
| Support Level | $2.06 | N/A |
| Resistance Level | $2.65 | $2.31 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 39.75 | 57.14 |
Price Performance
Historical ComparisonAbout ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.